Matches in SemOpenAlex for { <https://semopenalex.org/work/W2408247116> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2408247116 endingPage "1415" @default.
- W2408247116 startingPage "1411" @default.
- W2408247116 abstract "The efficacy and safety of combination therapy of 4 cycles with docetaxel 70 mg/m(2)every 3 weeks and trastuzumab as primary chemotherapy for operable breast cancer was determined in 21 patients (pts) by assessing the pathological complete response (pCR) rate, clinical response rate (RR), breast conservation surgery (BCS) rate and toxicities. To date, 19 pts have completed surgery. The pCR rate was 21% [95% CI 6%-46%] . The overall RR was 90% [95% CI 67%-99%] , with 5 CR, 12 PR, 2 SD and 0 PD. Grade 3 or 4 adverse events were leukopenia 48%, neutropenia 67%, hemoglobin 5%, and febrile neutropenia 10%. All non-hematological toxicities were mild and manageable. The pCR rate is not as low as that achieved in previous international studies. The combination of docetaxel and trastuzumab was a well-tolerated and very active regimen for the treatment of patients with HER 2-overexpressing operable breast cancer. This regimen promises to be one of the leading future treatments for progressive breast cancer." @default.
- W2408247116 created "2016-06-24" @default.
- W2408247116 creator A5000130194 @default.
- W2408247116 creator A5000846644 @default.
- W2408247116 creator A5004541129 @default.
- W2408247116 creator A5012661910 @default.
- W2408247116 creator A5023347677 @default.
- W2408247116 creator A5029247118 @default.
- W2408247116 creator A5035205901 @default.
- W2408247116 creator A5041980807 @default.
- W2408247116 creator A5058163170 @default.
- W2408247116 creator A5060702089 @default.
- W2408247116 creator A5071834091 @default.
- W2408247116 creator A5075058234 @default.
- W2408247116 creator A5081985303 @default.
- W2408247116 creator A5089611935 @default.
- W2408247116 date "2006-10-01" @default.
- W2408247116 modified "2023-09-23" @default.
- W2408247116 title "[Multicenter phase II trial of thrice-weekly docetaxel and weekly trastuzumab as preoperative chemotherapy in patients with HER 2-overexpressing breast cancer--Japan East Cancer Center Breast Cancer Consortium (JECBC) 02 Trial]." @default.
- W2408247116 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17033229" @default.
- W2408247116 hasPublicationYear "2006" @default.
- W2408247116 type Work @default.
- W2408247116 sameAs 2408247116 @default.
- W2408247116 citedByCount "1" @default.
- W2408247116 crossrefType "journal-article" @default.
- W2408247116 hasAuthorship W2408247116A5000130194 @default.
- W2408247116 hasAuthorship W2408247116A5000846644 @default.
- W2408247116 hasAuthorship W2408247116A5004541129 @default.
- W2408247116 hasAuthorship W2408247116A5012661910 @default.
- W2408247116 hasAuthorship W2408247116A5023347677 @default.
- W2408247116 hasAuthorship W2408247116A5029247118 @default.
- W2408247116 hasAuthorship W2408247116A5035205901 @default.
- W2408247116 hasAuthorship W2408247116A5041980807 @default.
- W2408247116 hasAuthorship W2408247116A5058163170 @default.
- W2408247116 hasAuthorship W2408247116A5060702089 @default.
- W2408247116 hasAuthorship W2408247116A5071834091 @default.
- W2408247116 hasAuthorship W2408247116A5075058234 @default.
- W2408247116 hasAuthorship W2408247116A5081985303 @default.
- W2408247116 hasAuthorship W2408247116A5089611935 @default.
- W2408247116 hasConcept C121608353 @default.
- W2408247116 hasConcept C126322002 @default.
- W2408247116 hasConcept C141071460 @default.
- W2408247116 hasConcept C143998085 @default.
- W2408247116 hasConcept C197934379 @default.
- W2408247116 hasConcept C2776694085 @default.
- W2408247116 hasConcept C2777063308 @default.
- W2408247116 hasConcept C2778850193 @default.
- W2408247116 hasConcept C2779786085 @default.
- W2408247116 hasConcept C2780873365 @default.
- W2408247116 hasConcept C2781190966 @default.
- W2408247116 hasConcept C2781413609 @default.
- W2408247116 hasConcept C530470458 @default.
- W2408247116 hasConcept C71924100 @default.
- W2408247116 hasConceptScore W2408247116C121608353 @default.
- W2408247116 hasConceptScore W2408247116C126322002 @default.
- W2408247116 hasConceptScore W2408247116C141071460 @default.
- W2408247116 hasConceptScore W2408247116C143998085 @default.
- W2408247116 hasConceptScore W2408247116C197934379 @default.
- W2408247116 hasConceptScore W2408247116C2776694085 @default.
- W2408247116 hasConceptScore W2408247116C2777063308 @default.
- W2408247116 hasConceptScore W2408247116C2778850193 @default.
- W2408247116 hasConceptScore W2408247116C2779786085 @default.
- W2408247116 hasConceptScore W2408247116C2780873365 @default.
- W2408247116 hasConceptScore W2408247116C2781190966 @default.
- W2408247116 hasConceptScore W2408247116C2781413609 @default.
- W2408247116 hasConceptScore W2408247116C530470458 @default.
- W2408247116 hasConceptScore W2408247116C71924100 @default.
- W2408247116 hasIssue "10" @default.
- W2408247116 hasLocation W24082471161 @default.
- W2408247116 hasLocation W24082471162 @default.
- W2408247116 hasOpenAccess W2408247116 @default.
- W2408247116 hasPrimaryLocation W24082471161 @default.
- W2408247116 hasRelatedWork W1984705515 @default.
- W2408247116 hasRelatedWork W2078915424 @default.
- W2408247116 hasRelatedWork W2104337757 @default.
- W2408247116 hasRelatedWork W2138222867 @default.
- W2408247116 hasRelatedWork W2139510434 @default.
- W2408247116 hasRelatedWork W2146384083 @default.
- W2408247116 hasRelatedWork W2149773268 @default.
- W2408247116 hasRelatedWork W2149908785 @default.
- W2408247116 hasRelatedWork W2151809511 @default.
- W2408247116 hasRelatedWork W2161791469 @default.
- W2408247116 hasRelatedWork W2171958606 @default.
- W2408247116 hasRelatedWork W2318605753 @default.
- W2408247116 hasVolume "33" @default.
- W2408247116 isParatext "false" @default.
- W2408247116 isRetracted "false" @default.
- W2408247116 magId "2408247116" @default.
- W2408247116 workType "article" @default.